サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1660885

尿路感染症（UTI）治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Urinary Tract Infection (UTI) Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 189 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
尿路感染症（UTI）治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年02月17日
発行: Persistence Market Research
ページ情報: 英文 189 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の尿路感染症（UTI）治療の市場規模は、2025年に103億7,000万米ドルになるとみられ、2025年～2032年の予測期間に5.5%のCAGRで拡大し、2032年には150億8,000万米ドルに達すると予測されています。

尿路感染症（UTI）治療市場には、尿路に影響を及ぼす細菌および真菌感染症の管理に使用される医薬品治療が含まれます。一般的に膀胱、尿道、腎臓に影響を及ぼすこれらの感染症は、世界的に広範な健康問題です。尿路結石の有病率の上昇、抗生物質耐性の増加、高齢者人口の増加が市場を牽引しています。新規抗生物質や代替治療法に関する継続的な研究が、市場の見通しをさらに形成しています。

不衛生、糖尿病などの慢性疾患、抗菌剤耐性の増加による尿路結石の発生率の上昇など、いくつかの要因が世界の尿路感染症（UTI）治療市場の成長に寄与しています。さらに、先進的な抗生物質療法や、プロバイオティクスやワクチンなどの非抗生物質代替品の開発が、市場拡大の原動力となっています。市販薬（OTC）の入手可能性や、尿路結石の早期診断・治療に対する意識の高まりも、市場の成長を後押ししています。

尿路感染症（UTI）治療市場は、特に薬剤製剤の進歩、ワクチン開発、早期発見・早期治療を可能にするポイントオブケア診断の台頭により、大きな機会をもたらしています。新規抗菌療法や植物療法（植物由来の薬）への投資は、新たな収益源を生み出すと期待されます。さらに、処方薬に簡単にアクセスできる遠隔医療やオンライン薬局の導入が増加していることも、市場へのアクセス性と成長性を高めています。

当レポートでは、世界の尿路感染症（UTI）治療市場について調査し、薬剤クラス別、用途別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因- 関連性と影響

第3章 付加価値の洞察

第4章 世界の尿路感染症（UTI）治療市場の見通し

  • 主なハイライト
  • 市場規模（10億米ドル）分析と予測
  • 世界の尿路感染症（UTI）治療市場の見通し：薬剤クラス別
  • 世界の尿路感染症（UTI）治療市場の見通し：用途別
  • 世界の尿路感染症（UTI）治療市場の見通し：流通チャネル別

第5章 世界の尿路感染症（UTI）治療市場の見通し：地域別

  • 主なハイライト
  • 過去の市場規模（10億米ドル）の分析、地域別、2019年-2024年
  • 現在の市場規模（10億米ドル）の分析と予測、地域別、2025年-2032年
    • 北米
    • 欧州
    • 東アジア
    • 南アジアとオセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域別

第6章 北米の尿路感染症（UTI）治療市場の見通し

第7章 欧州の尿路感染症（UTI）治療市場の見通し

第8章 東アジアの尿路感染症（UTI）治療市場の見通し

第9章 南アジアおよびオセアニアの尿路感染症（UTI）治療市場の見通し

第10章 ラテンアメリカの尿路感染症（UTI）治療市場の見通し

第11章 中東・アフリカの尿路感染症（UTI）治療市場の見通し

第12章 競合情勢

  • 市場シェア分析、2025年
  • 市場構造
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
    • Pfizer
    • Bayer AG
    • Almirall SA
    • GlaxoSmithKline Pharmaceuticals Ltd.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb
    • Shionogi & Co., Ltd
    • Cipla Inc.

第13章 付録

目次
Product Code: PMRREP33937

Persistence Market Research has recently released a comprehensive report on the global Urinary Tract Infection (UTI) Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Urinary Tract Infection (UTI) Treatment Market Size (2025E): USD 10.37 Bn
  • Projected Market Value (2032F): USD 15.08 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.5%

Urinary Tract Infection (UTI) Treatment Market - Report Scope:

The Urinary Tract Infection (UTI) Treatment Market encompasses pharmaceutical treatments used to manage bacterial and fungal infections affecting the urinary tract. These infections, which commonly impact the bladder, urethra, and kidneys, are a widespread global health concern. The market is driven by the rising prevalence of UTIs, increasing antibiotic resistance, and the growing geriatric population. Ongoing research in novel antibiotics and alternative treatment options is further shaping the market landscape.

Market Growth Drivers:

Several factors are contributing to the growth of the global UTI Treatment Market, including the increasing incidence of UTIs due to poor hygiene, chronic diseases like diabetes, and rising antimicrobial resistance. Additionally, the development of advanced antibiotic therapies and non-antibiotic alternatives such as probiotics and vaccines is driving market expansion. The availability of over-the-counter (OTC) medications and growing awareness about early diagnosis and treatment of UTIs are also fueling market growth.

Market Restraints:

Despite its positive growth trajectory, the UTI treatment market faces challenges, including the growing issue of antimicrobial resistance (AMR), which limits the effectiveness of conventional antibiotics. Strict regulatory frameworks and lengthy drug approval processes may also hinder market progress. Additionally, side effects associated with prolonged antibiotic use and the lack of awareness about UTI symptoms in certain regions pose hurdles to market expansion.

Market Opportunities:

The UTI Treatment Market presents significant opportunities, especially with advancements in drug formulations, vaccine development, and the rise of point-of-care diagnostics that enable early detection and treatment. Investment in novel antimicrobial therapies and phytotherapeutic treatments (plant-based medications) is expected to create new revenue streams. Additionally, the increasing adoption of telemedicine and online pharmacies for easy access to prescription drugs is enhancing market accessibility and growth potential.

Key Questions Answered in the Report:

  • What are the major factors driving growth in the UTI treatment market?
  • Which drug classes are expected to witness the highest demand?
  • How is antimicrobial resistance impacting the UTI treatment landscape?
  • Who are the leading players in the UTI treatment market, and what strategies are they adopting?
  • What are the emerging trends and future opportunities in the global UTI treatment market?

Competitive Intelligence and Business Strategy:

Leading pharmaceutical companies in the UTI Treatment Market, such as Pfizer, Bayer AG, and GlaxoSmithKline Pharmaceuticals Ltd., are focusing on drug innovation, strategic partnerships, and expanding their global distribution networks to maintain a competitive edge. These companies are also investing in clinical research and development of novel antibiotics and alternative therapies to combat antimicrobial resistance. Collaboration with healthcare providers and digital health platforms is another key strategy to enhance patient access to UTI medications and improve treatment outcomes.

Key Companies Profiled:

  • Pfizer
  • Bayer AG
  • Almirall SA
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb
  • Shionogi & Co., Ltd
  • Cipla Inc.

Urinary Tract Infection (UTI) Treatment Market Segmentation:

By Drug Class:

  • Penicillin and Combinations
  • Quinolones
  • Cephalosporins
  • Aminoglycoside Antibiotics
  • Sulphonamides (Sulfamethoxazole, Trimethoprim)
  • Azoles and Amphotericin B
  • Tetracycline (Doxycycline)
  • Nitrofurans (Nitrofurantoin)
  • Others

By Application:

  • Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection

By Distribution Channel:

  • Hospital Pharmacies
  • Gynecology and Urology Clinics
  • Drug Stores
  • Retail Pharmacies
  • Online Drug Stores

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Urinary Tract Infection (UTI) Treatment Market Outlook
  • 1.2. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Services
  • 1.3. Introduction/Key Findings
  • 1.4. Historical Market Size (US$ Bn) and Analysis, By Services, 2019 - 2024
  • 1.5. Current Market Size (US$ Bn) and Analysis and Forecast, By Services, 2025 - 2032
  • 1.6. Future Market Projections
  • 1.7. Premium Market Insights
  • 1.8. Industry Developments and Key Market Events
  • 1.9. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
  • 4.3. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
      • 4.3.3.1. Penicillin & Combinations
      • 4.3.3.2. Quinolones
      • 4.3.3.3. Cephalosporin
      • 4.3.3.4. Aminoglycoside Antibiotics
      • 4.3.3.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
      • 4.3.3.6. Azoles and Amphotericin B
      • 4.3.3.7. Tetracycline (Doxycycline)
      • 4.3.3.8. Nitrofurans (Nitrofurantoin)
      • 4.3.3.9. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
      • 4.4.3.1. Complicated Urinary Tract Infection
      • 4.4.3.2. Uncomplicated Urinary Tract Infection
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Distribution Channel
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 - 2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
      • 4.5.3.1. Hospital Pharmacies
      • 4.5.3.2. Gynecology and Urology Clinics
      • 4.5.3.3. Drug Stores
      • 4.5.3.4. Retail Pharmacies
      • 4.5.3.5. Online Drug Stores
    • 4.5.4. Market Attractiveness Analysis: Distribution Channel

5. Global Urinary Tract Infection (UTI) Treatment Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 6.4.1. Penicillin & Combinations
    • 6.4.2. Quinolones
    • 6.4.3. Cephalosporin
    • 6.4.4. Aminoglycoside Antibiotics
    • 6.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 6.4.6. Azoles and Amphotericin B
    • 6.4.7. Tetracycline (Doxycycline)
    • 6.4.8. Nitrofurans (Nitrofurantoin)
    • 6.4.9. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 6.5.1. Complicated Urinary Tract Infection
    • 6.5.2. Uncomplicated Urinary Tract Infection
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Gynecology and Urology Clinics
    • 6.6.3. Drug Stores
    • 6.6.4. Retail Pharmacies
    • 6.6.5. Online Drug Stores
  • 6.7. Market Attractiveness Analysis

7. Europe Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 7.4.1. Penicillin & Combinations
    • 7.4.2. Quinolones
    • 7.4.3. Cephalosporin
    • 7.4.4. Aminoglycoside Antibiotics
    • 7.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 7.4.6. Azoles and Amphotericin B
    • 7.4.7. Tetracycline (Doxycycline)
    • 7.4.8. Nitrofurans (Nitrofurantoin)
    • 7.4.9. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 7.5.1. Complicated Urinary Tract Infection
    • 7.5.2. Uncomplicated Urinary Tract Infection
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Gynecology and Urology Clinics
    • 7.6.3. Drug Stores
    • 7.6.4. Retail Pharmacies
    • 7.6.5. Online Drug Stores
  • 7.7. Market Attractiveness Analysis

8. East Asia Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 8.4.1. Penicillin & Combinations
    • 8.4.2. Quinolones
    • 8.4.3. Cephalosporin
    • 8.4.4. Aminoglycoside Antibiotics
    • 8.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 8.4.6. Azoles and Amphotericin B
    • 8.4.7. Tetracycline (Doxycycline)
    • 8.4.8. Nitrofurans (Nitrofurantoin)
    • 8.4.9. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 8.5.1. Complicated Urinary Tract Infection
    • 8.5.2. Uncomplicated Urinary Tract Infection
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Gynecology and Urology Clinics
    • 8.6.3. Drug Stores
    • 8.6.4. Retail Pharmacies
    • 8.6.5. Online Drug Stores
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 9.4.1. Penicillin & Combinations
    • 9.4.2. Quinolones
    • 9.4.3. Cephalosporin
    • 9.4.4. Aminoglycoside Antibiotics
    • 9.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 9.4.6. Azoles and Amphotericin B
    • 9.4.7. Tetracycline (Doxycycline)
    • 9.4.8. Nitrofurans (Nitrofurantoin)
    • 9.4.9. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 9.5.1. Complicated Urinary Tract Infection
    • 9.5.2. Uncomplicated Urinary Tract Infection
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Gynecology and Urology Clinics
    • 9.6.3. Drug Stores
    • 9.6.4. Retail Pharmacies
    • 9.6.5. Online Drug Stores
  • 9.7. Market Attractiveness Analysis

10. Latin America Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 10.4.1. Penicillin & Combinations
    • 10.4.2. Quinolones
    • 10.4.3. Cephalosporin
    • 10.4.4. Aminoglycoside Antibiotics
    • 10.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 10.4.6. Azoles and Amphotericin B
    • 10.4.7. Tetracycline (Doxycycline)
    • 10.4.8. Nitrofurans (Nitrofurantoin)
    • 10.4.9. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 10.5.1. Complicated Urinary Tract Infection
    • 10.5.2. Uncomplicated Urinary Tract Infection
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Gynecology and Urology Clinics
    • 10.6.3. Drug Stores
    • 10.6.4. Retail Pharmacies
    • 10.6.5. Online Drug Stores
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urinary Tract Infection (UTI) Treatment Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Application
    • 11.2.4. By Distribution Channel
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    • 11.4.1. Penicillin & Combinations
    • 11.4.2. Quinolones
    • 11.4.3. Cephalosporin
    • 11.4.4. Aminoglycoside Antibiotics
    • 11.4.5. Sulphonamides (Sulfamethoxazole, Trimethoprim)
    • 11.4.6. Azoles and Amphotericin B
    • 11.4.7. Tetracycline (Doxycycline)
    • 11.4.8. Nitrofurans (Nitrofurantoin)
    • 11.4.9. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025 - 2032
    • 11.5.1. Complicated Urinary Tract Infection
    • 11.5.2. Uncomplicated Urinary Tract Infection
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 - 2032
    • 11.6.1. Hospital Pharmacies
    • 11.6.2. Gynecology and Urology Clinics
    • 11.6.3. Drug Stores
    • 11.6.4. Retail Pharmacies
    • 11.6.5. Online Drug Stores
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Pfizer
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Bayer AG
    • 12.3.3. Almirall SA
    • 12.3.4. GlaxoSmithKline Pharmaceuticals Ltd.
    • 12.3.5. Merck & Co., Inc.
    • 12.3.6. Bristol-Myers Squibb
    • 12.3.7. Shionogi & Co., Ltd
    • 12.3.8. Cipla Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations